卢美哌隆治疗双相I型或II型障碍相关重性抑郁发作的3期随机安慰剂对照试验
本3期随机双盲安慰剂对照研究纳入18-75岁双相I型或II型障碍伴重性抑郁发作患者,按1:1随机接受卢美哌隆42 mg/日(N=188)或安慰剂(N=189)治疗6周。第43天时,卢美哌隆组MADRS评分改善显著优于安慰剂(最小二乘均值差-4.6分,效应量-0.56),CGI-BP-S总分亦显著优于安慰剂(最小二乘均值差-0.9,效应量-0.46)。嗜睡和恶心是仅有的临床意义高于安慰剂的不良事件,锥体外系症状相关不良事件发生率低且与安慰剂相似,体重、生命体征及代谢内分泌指标变化极小。
要点
- 卢美哌隆42 mg/日治疗6周显著改善双相I型和II型相关重性抑郁发作的抑郁症状。
- 嗜睡和恶心是仅有的临床意义高于安慰剂的不良事件,锥体外系症状发生率低。
- 体重、生命体征及代谢内分泌指标变化极小,总体耐受性良好。
核心结论
- 卢美哌隆42 mg/日显著改善双相I型和II型障碍相关重性抑郁发作的抑郁症状,且总体耐受性良好。
研究设计与样本
- 3期随机双盲安慰剂对照研究,纳入18-75岁临床诊断为双相I型或II型障碍且处于重性抑郁发作的患者。
- 患者按1:1随机接受卢美哌隆42 mg/日(N=188)或安慰剂(N=189),每晚口服一次,治疗6周。
主要发现
- 第43天,卢美哌隆组MADRS评分较基线的改善显著优于安慰剂,最小二乘均值差为-4.6分,效应量为-0.56。
- 第43天,卢美哌隆组CGI-BP-S总分较基线的改善显著优于安慰剂,最小二乘均值差为-0.9,效应量为-0.46。
- 在双相I型和双相II型患者中均观察到卢美哌隆对MADRS的显著优势。
- 嗜睡和恶心是仅有的临床意义高于安慰剂的治疗中出现的不良事件。
- 锥体外系症状相关治疗中出现的不良事件发生率低且与安慰剂相似,体重、生命体征及代谢或内分泌评估变化极小。
关键数值与推荐
- 主要疗效终点为第43天MADRS评分较基线的变化,关键次要疗效终点为CGI-BP-S总分较基线的变化。
- 卢美哌隆42 mg/日组MADRS最小二乘均值差-4.6分(效应量-0.56),CGI-BP-S最小二乘均值差-0.9(效应量-0.46)。
临床怎么用
- 对于双相I型或II型障碍相关重性抑郁发作,卢美哌隆42 mg/日每晚一次口服治疗6周可显著改善抑郁症状。
- 用药期间需关注嗜睡和恶心,锥体外系症状及代谢指标变化风险较低但仍应常规监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In a phase 3 randomized double-blind placebo-controlled study, the authors investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or bipolar II disorder experiencing a major depressive episode. METHODS: Patients 18-75 years old with a clinical diagnosis of bipolar I or bipolar II disorder and experiencing a major depressive episode were eligible for the study. Patients were randomized in a 1:1 ratio to receive 42 mg/day of lumateperone (N=188) or placebo (N=189), administered orally once daily in the evening for 6 weeks. The primary and key secondary efficacy endpoints were change from baseline to day 43 in score on the Montgomery-Åsberg Depression Rating Scale (MADRS) and total score on the Clinical Global Impressions Scale-Bipolar Version severity scale (CGI-BP-S), respectively. Safety assessments included treatment-emergent adverse events, laboratory parameters, vital signs, extrapyramidal symptoms, and suicidality. RESULTS: At day 43, lumateperone treatment was associated with significantly greater improvement from baseline in MADRS score compared with placebo (least squares mean difference compared with placebo, -4.6 points; effect size=-0.56) and CGI-BP-S total score (least squares mean difference compared with placebo, -0.9; effect size=-0.46). Significant MADRS superiority for lumateperone over placebo was observed both in patients with bipolar I and bipolar II disorders. Somnolence and nausea were the only treatment-emergent adverse events that occurred with lumateperone at a clinically meaningful greater rate than placebo. The incidence of extrapyramidal symptom-related treatment-emergent adverse events was low and similar to that for placebo. Minimal changes were observed in weight, vital signs, or metabolic or endocrine assessments. CONCLUSIONS: Lumateperone at 42 mg/day significantly improved depression symptoms and was generally well tolerated in patients with major depressive episodes associated with both bipolar I and bipolar II disorders.
引用
- Calabrese JR, Durgam S, Satlin A, et al. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry. 2021. PMID: 34551584. doi:10.1176/appi.ajp.2021.20091339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。